Stirling reports positive preliminary trial results
Tuesday, 30 November, 2004
Stirling Products (ASX: STI) has reported that preliminary results from the trials of its lead product ST810 (R-salbutamol) in pigs indicate significantly higher potency than expected, with economic viability at the lowest dose tested.
Final results from the trial, which was conducted in the US by the USDA's Swine Research Unit, will be released early in 2005. The trial was designed to measure physiological and behavioural parameters including weight gain, feed conversion, increase in lean meat and decrease in fat content.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
